Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VTVT
Strong SellSinkervTv Therapeutics Inc. · Healthcare · United States · $128M · Avg Vol: $2M/d
COMPANY DESCRIPTION
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates for challenging metabolic and inflammatory diseases. The company leverages its proprietary drug discovery platform to target underlying disease mechanisms, advancing a pipeline of potential therapies through clinical trials. Its competitive position relies on its ability to successfully navigate the complex drug development process and bring innovative treatments to market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.0M | 0 | 1.0M | 0 | -29.0% | — | 27.9M | — | 423.8% |
| EPS | -10.40 | -9.71 | -3.20 | -3.20 | — | -0.75 | -2.22 | -4.29 | — |
| Shares | 2.0M | 2.1M | 2.6M | 3.9M | +93.3% | 4.0M | — | — | — |
| Debt | 0.7M | 0.5M | 0.2M | 0 | -51.4% | — | — | — | — |
| Equity | -10.7M | -24.7M | 12.2M | 64.4M | 428.2% | — | — | — | — |
| Op CF | -16.0M | -19.1M | -25.3M | -25.3M | — | -16.8M | — | — | — |
| Inv CF | -21.0K | 4.4M | 0 | 0 | — | — | — | — | — |
| Fin CF | 14.8M | 12.0M | 52.6M | 77.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VTVT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VTVT | vTv Therapeutics Inc.(you) | $128M | 18 | Strong Sell |
| AARD | Aardvark Therapeutics, Inc. | $127M | 18 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| GUTS | Fractyl Health, Inc. | $105M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%